Loading
Illumina's kit that lets a hospital or research laboratory run a large cancer gene panel itself instead of sending the sample away.
TruSight Oncology 500 is Illumina's comprehensive genomic profiling kit. Version 2 sequences DNA from 523 genes and RNA from 55 genes from formalin-fixed tissue, detecting single-nucleotide variants, copy number changes, insertions and deletions, fusions and large BRCA1/2 rearrangements, and reports microsatellite instability and tumour mutational burden, in 3 to 4 days from sample to result. Homologous recombination deficiency analysis, a genomic instability score combining loss of heterozygosity, telomeric allelic imbalance and large-scale state transitions powered by Myriad Genetics, is built into the workflow and licensed separately. A ctDNA version analyses plasma with similar DNA content. The kit is for research use only and not for diagnostic procedures; Illumina's FDA-approved diagnostic panel is TruSight Oncology Comprehensive.
A hybrid-capture kit that a laboratory runs on its own Illumina sequencer: DNA from 523 genes and RNA from 55 genes, with tumour mutational burden, microsatellite instability and an optional homologous recombination deficiency score.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TruSight Oncology 500" OR ABSTRACT:"TruSight Oncology 500" OR TITLE:"Illumina TruSight Oncology 500" OR ABSTRACT:"Illumina TruSight Oncology 500" OR TITLE:"TSO 500" OR ABSTRACT:"TSO 500" OR TITLE:"TruSight Oncology 500 v2" OR ABSTRACT:"TruSight Oncology 500 v2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TruSight Oncology 500, not a curated reading list.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Homologous recombination deficiency (HRD), Tumour mutational burden (TMB) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), MSI-high (microsatellite instability by PCR or sequencing), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares Homologous recombination deficiency (HRD), Tumour mutational burden (TMB), Next-generation sequencing (NGS), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR) and the tag test.
Shares TMB-high (tumour mutational burden >= 10 mutations per megabase), Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares MSI-high (microsatellite instability by PCR or sequencing), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR) and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/